Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
FABm006-01 | Mouse | PE-Labeled Monoclonal Anti-Human CD56 Antibody |
|
Flow cytometric analysis of Human peripheral blood lymphocytes respectively staining with PE-Labeled Monoclonal Anti-Human CD56 Antibody Mouse IgG2b (Cat. No. FABm006-01) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Rhabdomyosarcoma; Ovarian Neoplasms; Leukemia; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Sarcoma, Synovial; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Carcinoma, Small Cell | Details |
CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Rhabdomyosarcoma; Ovarian Neoplasms; Leukemia; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Sarcoma, Synovial; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Carcinoma, Small Cell | Details |
CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
This web search service is supported by Google Inc.